December 6, 2011
Bristol-Myers Squibb Co. and Johnson & Johnson said Friday they will work together to develop experimental treatments for hepatitis C virus. BMS said its drugs daclatasir (BMS-790052) and its NS5A replication complex inhibitor will be tested in combination with the NS3 protease inhibitor (TMC435) under development by J&J's Tibotec unit. Beginning in the first half of 2012, the medicines, which seek to block different proteins than those usually targeted by HCV treatments, will be tested in various combinations among patients with genotype 1, the most common and hard-to-treat HCV strain. Several companies are working to develop HCV treatments that do not include interferon, whose flu-like side effects cause many patients to avoid or discontinue treatment.
12.02.2011; Ransdell Pierson; Bill Berkrot
No comments have been made.
|Using Saliva as Lube Can Cause Rectal Gonorrhea|
|This Week in HIV Research: Enzyme May Reduce Cardiovascular Disease Risk, and New Insights Into an HIV Vaccine|
|This Week in HIV Research: Determinants of Cognitive Impairment, and Discovery of 'Teenage' Broadly Neutralizing Antibody|
|FDA Approves Descovy, an Updated Version of Truvada -- But Not for PrEP|
|What Should the Next U.S. President Do to Advance the Fight Against HIV?|